Company Launches 16 New Products, Shares Surge by 9% to All-Time High
JFL Life Sciences Limited, a company involved in the manufacturing of pharmaceutical products, experienced a surge in its share price by 9 percent, reaching an all-time 52-week high of Rs 63.85 per share. This increase came after the firm announced the launch of 16 new products in various categories such as Tablets, Capsules, Gel, Syrup, and Injections to cater to the domestic market under the Make in India campaign.
The company’s shares, with a market capitalization of Rs 59.50 crores, had fallen by around 7 percent and closed at Rs 54.50 apiece on the previous trading day. Despite this recent dip, the shares of JFL Life Sciences Limited have generated an impressive overall return of 39 percent over the past year and 37.76 percent over the past 6 months.
In terms of financial performance, the company reported a year-on-year increase in revenues from Rs 42.83 crores in FY23 to Rs 46.55 crores in FY24. Similarly, the net profits also saw a significant rise from Rs 2.81 crores to Rs 3.31 crores, indicating a 17.7 percent increase.
Furthermore, JFL Life Sciences Limited reported return ratios for the year 2024, including a return on equity (ROE) of 9.30 percent and a return on capital employed (ROCE) of 12.62 percent. The company also maintained a healthy debt-to-equity ratio of 0.16 times in the same year.
With a diverse product portfolio that includes popular offerings like J Cold Gold tablet, J-Reb DSR capsule, and J-Finance P tablet, JFL Life Sciences Limited has established itself as a key player in the pharmaceutical industry. The company’s shareholding pattern as of March 2024 shows 67.47 percent ownership by promoters and 32.53 percent held by the public.
Founded in 2010, JFL Life Sciences Limited operates manufacturing facilities in Kerala, Bavla, Ahmedabad, and Gujarat. The recent launch of 16 new products underscores the company’s commitment to innovation and growth in the pharmaceutical sector.
Investors are advised to exercise caution and consult with their investment advisors before making any decisions based on this news. The views and investment tips expressed in this article are those of the experts and not necessarily reflective of the website or its management.